Maximum quantity allowed is 999
请选择数量
CAS RN: 72956-09-3 | 產品號碼: C2260
產品規格
Appearance | White to Almost white powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Nonaqueous Titration) | min. 98.0 % |
Melting point | 115.0 to 119.0 °C |
性質
熔點 | 117 °C |
水溶性 | Insoluble |
溶解性(可溶於) | Methanol |
溶解性(微溶於) | Ether, Ethanol |
GHS
圖形表示 |
![]() |
危險性說明 | H411 : Toxic to aquatic life with long lasting effects. |
防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P391 : Collect spillage. |
相關法規
RTECS # | UA8670000 |
運輸資料
UN編號 | UN3077 |
類別 | 9 |
包裝類別 | III |
HS編碼* | 2933.99-000 |
Application
Carvedilol: A Nonselective β-Adrenoceptor Antagonist with α1-Receptor Antagonistic Activity
Carvedilol is a nonselective β1 and β2-adrenoceptor antagonist1) with α1-receptor antagonistic activity.2) The ratio of β1:β2 adrenergic activity is 7:1,1) and the ratio of α:β adrenergic activity is 1:8.3) Carvedilol is a racemic mixture, and the β-adrenoreceptor blocking activity is present in the S-(-)-enantiomer and α1-adrenergic blocking activity is present in both R-(+) and S-(-)-enantiomers at equal potency.4) Carvedilol also has antioxidant and antiproliferative effects.5) Furthermore, carvedilol is able to stimulate β-arrestin-mediated signaling.6) (The product is for research purpose only.)
References
- 1)Pharmacological Profile of Carvedilol as a β-Blocking Agent with Vasodilating and Hypotensive Properties.
- 2)Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation
- 3)Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine
- 4)Clinical pharmacokinetics and pharmacodynamics of carvedilol (a review)
- 5)Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger (a review)
- 6)A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling
考研文獻
TCIMail
產品文件 (部分產品的分析圖譜無法提供,敬請諒解。)